|
業務類別
|
Biotechnology |
|
業務概覽
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
| 公司地址
| 780 Brannan Street, San Francisco, CA, USA, 94103 |
| 電話號碼
| +1 415 651-3316 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.olema.com |
| 員工數量
| 131 |
| Dr. Sean P. Bohen, M.D.,PhD |
Director, President, Chief Executive Officer and Interim Principal Financial Officer |
美元 699.92K |
30/01/2026 |
| Ms. Shawnte M. Mitchell, J.D. |
Chief Legal Officer and Corporate Secretary |
美元 391.88K |
29/04/2026 |
| Dr. David C. Myles, PhD |
Chief Scientific Officer |
-- |
29/04/2026 |
| Dr. Naseem Zojwalla, M.D. |
Chief Medical Officer |
-- |
29/04/2026 |
| Ms. Sasha Lu Austin |
Vice President, Finance and Controller |
-- |
16/03/2026 |
|
|
| Mr. Andrew S. Rappaport |
Independent Director |
29/04/2026 |
| Ms. Cynthia M. Butitta |
Independent Director |
29/04/2026 |
| Mr. Ian T. Clark |
Chairman of the Board |
29/04/2026 |
| Dr. Sandra J. Horning, M.D. |
Independent Director |
29/04/2026 |
| Mr. Scott Garland |
Independent Director |
29/04/2026 |
| Dr. Sean P. Bohen, M.D.,PhD |
Director, President, Chief Executive Officer and Interim Principal Financial Officer |
30/01/2026 |
| Dr. Graham Walmsley, M.D.,PhD |
Independent Director |
29/04/2026 |
| Ms. Yi Larson |
Independent Director |
29/04/2026 |
| Dr. Gorjan Hrustanovic, PhD |
Independent Director |
29/04/2026 |
| Dr. Cyrus L. Harmon, PhD |
Independent Director |
29/04/2026 |
| Dr. Prakash Raman, PhD |
Independent Director |
29/04/2026 |
|
|
|
|
